For the quarter ended September 2024, Boston Scientific (BSX) reported revenue of $4.21 billion, up 19.3% over the same period last year. EPS came in at $0.63, compared to $0.50 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $4.03 billion, representing a surprise of +4.35%. The company delivered an EPS surprise of +8.62%, with the consensus EPS estimate being $0.58.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

文章核心观点 - 波士顿科学公司第三季度业绩超出市场预期,每股收益为0.63美元,高于市场预期的0.58美元 [1] - 公司连续4个季度超出市场盈利预期 [1] - 公司第三季度收入为42.1亿美元,也超出市场预期 [1] - 公司股价今年以来上涨52.2%,大幅跑赢标普500指数 [2] 公司业绩 - 公司第三季度每股收益0.63美元,超出市场预期0.58美元,同比增长26% [1] - 公司第三季度收入42.1亿美元,超出市场预期4.35% [1] - 公司连续4个季度超出市场盈利预期 [1] 行业表现 - 医疗器械行业目前在250多个扎克斯行业中排名前27% [5] - 扎克斯研究显示,排名前50%的行业相比排名后50%的行业,业绩表现会好2倍以上 [5] - 另一家同行业公司Canopy Growth第三季度预计每股亏损0.38美元,同比减亏78.9% [5] - Canopy Growth第三季度收入预计为4684万美元,同比下降9.7% [5]

净销售额增长 - 第三季度净销售额为42.09亿美元，同比增长19.4%（报告基础），19.5%（运营基础），18.2%（有机基础）[1][2] - 各业务部门净销售额增长：MedSurg部门增长10.3%（报告基础），10.4%（运营基础），7.7%（有机基础）；Cardiovascular部门增长25.0%（报告基础），25.1%（运营基础），24.6%（有机基础）[2] - 各地区净销售额增长：美国增长23.5%（报告和运营基础）；EMEA地区增长15.2%（报告基础），14.3%（运营基础）；亚太地区增长12.1%（报告基础），12.3%（运营基础）；拉美和加拿大增长9.0%（报告基础），15.1%（运营基础）；新兴市场增长15.2%（报告基础），16.8%（运营基础）[2] - 公司预计全年净销售额增长约16.5%（报告基础），15%（有机基础）[9] - 第四季度净销售额预计增长16.5%至18.5%（报告基础），14%至16%（有机基础）[10] - 公司预计第四季度净销售额增长16.5%至18.5%（报告基础），14%至16%（有机基础）[10] - 公司预计全年净销售额增长约16.5%（报告基础），15%（有机基础）[9] - 2024年第三季度净销售额为42.09亿美元，同比增长19.3%[16] - 2024年前九个月净销售额为121.86亿美元，同比增长15.9%[16] - 公司2023年第三季度总收入为7,317百万美元，同比增长16.5%至18.5%[21] - 公司2023年第三季度调整后总收入为7,452百万美元，同比增长14.0%至16.0%[21] 净利润和每股收益 - 第三季度GAAP净利润为4.69亿美元，每股收益（EPS）为0.32美元，调整后EPS为0.63美元[1][2] - 公司预计全年GAAP EPS为1.28至1.30美元，调整后EPS为2.45至2.47美元[9] - 第四季度预计GAAP EPS为0.41至0.43美元，调整后EPS为0.64至0.66美元[10] - 2024年第三季度净利润为4.69亿美元，同比下降7.3%[16] - 2024年第三季度每股收益（基本）为0.32美元，同比下降5.9%[16] - 2024年第三季度非GAAP调整后净利润为9.37亿美元，同比增长89.5%[17] - 2024年第三季度非GAAP调整后每股收益为0.63美元，同比增长85.3%[17] - 公司2023年第三季度GAAP净利润为1,065百万美元，调整后净利润为2,181百万美元[20] - 公司2024年第四季度预计GAAP每股收益为0.41至0.43美元，调整后每股收益为0.64至0.66美元[22] - 公司2024年全年预计GAAP每股收益为1.28至1.30美元，调整后每股收益为2.45至2.47美元[22] 财务指标和业绩评估 - 公司使用非GAAP财务指标来评估业绩和分配资源，这些指标包括调整后净利润、调整后每股收益、运营净销售额和有机净销售额[23][24][25][26][27] 业务发展和产品批准 - 公司完成了对Silk Road Medical的收购，该公司专注于预防中风的产品[4] - 公司获得了多项新产品批准，包括FARAWAVE™ NAV消融导管、FARAVIEW™软件、FARAPULSE PFA系统、ACURATE Prime™主动脉瓣系统等[3][4] 其他财务数据 - 2024年第三季度毛利润为28.97亿美元，同比增长19.4%[16] - 2024年第三季度营业利润为7.33亿美元，同比增长5.8%[16] - 2024年前九个月毛利润为83.95亿美元，同比增长14.7%[16] - 2024年前九个月营业利润为19.28亿美元，同比增长9.6%[16]

UKRAINE - 2021/06/17: In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesBoston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates. The company should continue to benefit fr ...

New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablationMARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the navigation-enabled FARAWAVE™ NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) and FDA 510(k) clearance for the new FARAVIEW™ Software, which will combi ...

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast revenues of $4.03 billion, representing an increase of 14.4% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a co ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Considering buying BSX stock? Here’s what analysts think: Read More: ...

Boston Scientific (BSX) closed the most recent trading day at $87, moving +0.27% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.47%. On the other hand, the Dow registered a gain of 0.79%, and the technology-centric Nasdaq increased by 0.28%.Heading into today, shares of the medical device manufacturer had gained 5.15% over the past month, outpacing the Medical sector's loss of 4.27% and the S&P 500's gain of 3.48% in that time.The investment community wil ...

The market expects Boston Scientific (BSX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be ...

Boston Scientific Corporation (BSX) is scheduled to report third-quarter 2024 results on Oct. 23, before the opening bell.In the last reported quarter, the company’s earnings per share of 62 cents exceeded the Zacks Consensus Estimate by 6.9%. BSX’s bottom line beat estimates in each of the trailing four quarters. The company delivered a trailing four-quarter earnings surprise of 7.18%, on average.Q3 EstimatesThe Zacks Consensus Estimate for third-quarter total revenues is pegged at $4.03 billion, suggestin ...